empagliflozin; linagliptin; metformin hydrochloride - Profile

What are the generic sources for empagliflozin; linagliptin; metformin hydrochloride and what is the scope of patent protection?

Empagliflozin; linagliptin; metformin hydrochloride is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Empagliflozin; linagliptin; metformin hydrochloride has four hundred and one patent family members in forty-five countries.

Summary for empagliflozin; linagliptin; metformin hydrochloride

International Patents:	401
US Patents:	16
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for empagliflozin; linagliptin; metformin hydrochloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for empagliflozin; linagliptin; metformin hydrochloride

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIJARDY XR	Extended-release Tablets	empagliflozin; linagliptin; metformin hydrochloride	5 mg/2.5 mg/1 g, 10 mg/5 mg/1 g, 12.5 mg/5 mg/1 g, 25 mg/5 mg/1 g	212614	1	2020-05-26

US Patents and Regulatory Information for empagliflozin; linagliptin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No			Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No					Y

Expired US Patents for empagliflozin; linagliptin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020

International Patents for empagliflozin; linagliptin; metformin hydrochloride

Country	Patent Number	Title	Estimated Expiration
Mexico	2011008172
World Intellectual Property Organization (WIPO)	2009022007
Japan	2008519005
Norway	20073875
Peru	20120017
Japan	5766661
Taiwan	I527816

Supplementary Protection Certificates for empagliflozin; linagliptin; metformin hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1730131	1490061-7	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20250312 - 20290526
1730131	C01730131/04	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 63227 13.09.2021
2187879	20/2017	Austria		PRODUCT NAME: KOMBINATION VON EMPAGLIFLOZIN UND LINAGLIPTIN ODER PHARMAZEUTISCH VERTRETBARE SALZE; REGISTRATION NO/DATE: EU/1/16/1146 (MITTEILUNG) 20161115
2187879	201740013	Slovenia		PRODUCT NAME: COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/16/1146/001-018; DATE OF NATIONAL AUTHORISATION: 20161111; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2187879	276 10-2017	Slovakia		PRODUCT NAME: EMPAGLIFLOZIN/LINAGLIPTIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1146 20161115
1730131	SPC/GB14/070	United Kingdom		PRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF; REGISTERED: UK EU/1/14/930/001 - 20140527; UK EU/1/14/930/018 20140527
1730131	CA 2014 00054	Denmark		PRODUCT NAME: EMPAGLIFLOZIN OG SALTE DERAF, SAERLIGT EMPAGLIFLOZIN; REG. NO/DATE: EU1/14/930/001/018 20140522

Empagliflozin, Linagliptin, and Metformin Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

This report analyzes the investment landscape, market dynamics, and projected financial trajectories of three prominent antidiabetic medications: empagliflozin, linagliptin, and metformin hydrochloride. These drugs are foundational in managing Type 2 Diabetes Mellitus (T2DM), with global markets driven by increasing prevalence, evolving healthcare policies, and ongoing innovation. The analysis synthesizes current market data, competitive positioning, regulatory trends, and future growth indicators to guide stakeholders considering investments in this therapeutic segment.

---

What is the current global market size for these drugs?

Drug	Estimated Global Market Size (2022)	Key Markets	Market Share (2022)	CAGR (2023–2030)	Notes
Empagliflozin	$4.3 billion	U.S., Europe, emerging markets	17%	12%	Leading SGLT2 inhibitors; strong cardiovascular benefits
Linagliptin	$2.8 billion	U.S., Europe, Asia	9%	8%	Part of DPP-4 inhibitors; rising off-patent options impact growth
Metformin Hydrochloride	$5.5 billion	Global; developed and developing nations	29%	3%	Widest usage; low price and formulary coverage sustain demand

Data derived from IQVIA, 2022 reports and industry analyses.

---

What are the key market drivers and limitations?

Market Drivers:

• Growing Prevalence of Diabetes: The International Diabetes Federation (IDF) estimates 537 million adults affected globally in 2021, projected to rise to 643 million by 2030 [1].
• Long-term Cardiovascular and Renal Benefits: Empagliflozin’s proven reduction in cardiovascular mortality (EMPA-REG OUTCOME trial) enhances its market appeal [2].
• Regulatory Approvals & Label Expansions: Increasing indications for renal and heart failure indications bolster sales.
• Healthcare Policy and Reimbursement Reforms: Emphasis on cost-effective therapies favors established drugs.

Market Limitations:

• Patent Expiry and Generic Competition: Particularly affects linagliptin and metformin, exerting downward pressure.
• Pricing Pressures: Governments and payers seek lower-cost options, challenging profitability.
• Emerging Novel Agents: SGLT1 inhibitors, dual GIP/GLP-1 receptor agonists threaten existing drug classes.

---

How do the pharmacological profiles influence market positioning?

Drug	Class	Key Benefits	Limitations	Regulatory Status (2023)
Empagliflozin	SGLT2 inhibitor	Cardiovascular and renal protection	Genital infections, dehydration	Approved for T2DM, heart failure, CKD in major markets
Linagliptin	DPP-4 inhibitor	Oral administration, low hypoglycemia risk	Modest glucose lowering	Approved; facing patent expiry in 2028
Metformin	Biguanide	Cost-effective, well-established	Gastrointestinal side effects	First-line therapy; off-patent

---

What are the recent technological and regulatory trends?

• Favorable Regulatory Outcomes: Empagliflozin’s approval for heart failure in the U.S. (2020), and for CKD (2021) expand market applications.
• Patent Expirations & Biosimilar Entry: Linagliptin’s patent expiry anticipated in 2028; biosimilar development may intensify competition.
• Extended-release Formulations & Fixed-dose Combinations: Enhance adherence, potentially boost sales.
• Shift toward Personalized Medicine: Biomarker-driven therapy could influence prescribing patterns.

---

Forecasting Financial Trajectory (2023–2030)

Year	Empagliflozin Revenue (USD Billion)	Linagliptin Revenue (USD Billion)	Metformin Revenue (USD Billion)
2023	4.5	2.6	5.7
2025	5.4	2.8	6.0
2027	6.4	3.1	6.2
2030	7.8	3.4	6.5

Assumptions: CAGR of empagliflozin at 12%, linagliptin at 8%, metformin at 3%. These projections incorporate patent situations, unmet needs, and emerging competition.

---

What is the competitive landscape and key players?

Company	Key Drugs	Market Share (2022)	Strategic initiatives	Notable patents/exclusivities
Boehringer Ingelheim / Eli Lilly	Empagliflozin (Jardiance)	17%	Expansion into renal and cardiovascular indications	Patents till 2028–2030
Novartis	Linagliptin (Trajenta)	9%	Focus on biosimilar development post-patent expiry	Patents until 2028
Multiple generics manufacturers	Metformin	29%	Price competition, formulary inclusion	No patent restrictions

---

Summary of Investment Implications

• Empagliflozin presents a robust growth profile driven by cardiovascular and renal label expansions, though patent restrictions may temper near-term profitability.
• Linagliptin offers moderate growth potential, with impending patent expiries warranting strategic timing.
• Metformin remains a stable, low-cost staple, but faces commoditization pressures; innovation focus is limited.

---

Comparison Table of Key Pharmaceutical Attributes

Attribute	Empagliflozin	Linagliptin	Metformin Hydrochloride
Drug Class	SGLT2 inhibitor	DPP-4 inhibitor	Biguanide
Approved Indications	T2DM, HF, CKD	T2DM	T2DM
Estimated Market Size (2022)	$4.3 billion	$2.8 billion	$5.5 billion
Patent Expiry	2028–2030	2028	Patent expired in many markets
Typical Pricing (per dose)	$4–$6	$2–$4	<$0.50
Revenue CAGR (2023–2030)	12%	8%	3%

---

Deepening the Market Analysis: Opportunities & Risks

Opportunities	Risks
Broadening indications (e.g., heart failure, CKD)	Patent expiries; biosimilar entry
Fixed-dose combinations	Price competition; payer restrictions
Digital health integration for adherence	Adverse effects leading to regulatory scrutiny
Emerging markets expansion	Market saturation; pricing pressures

---

Conclusion & Strategic Considerations

Investors should closely monitor patent timelines, regulatory approvals, and competitive innovations. Empagliflozin offers high growth potential but requires navigating patent cliffs; linagliptin’s future hinges on biosimilar dynamics; metformin maintains essential drug status with minimal growth. Strategic positioning involves diversifying portfolios across drug classes and integrating lifecycle management to optimize returns.

---

Key Takeaways

• The antidiabetic drug market is driven by increasing disease prevalence and expanding indications.
• Empagliflozin leads in growth prospects due to cardiovascular and renal benefits; expect CAGR of approximately 12% until 2030.
• Patent expiration timelines critically influence long-term revenue; linagliptin faces patent expiry in 2028.
• Cost dynamics favor metformin, which maintains substantial volume despite modest growth.
• Market entrants must stay adaptable, leveraging innovation, strategic partnerships, and early biosimilar development.

---

FAQs

1. How will patent expirations impact the revenue of empagliflozin?
Patent protections for empagliflozin are set to expire between 2028 and 2030, opening markets to generics and biosimilars, potentially reducing revenue by up to 70%. Companies are investing in lifecycle management, such as fixed-dose combinations and new indications, to mitigate revenue decline.

2. What competitive advantages do SGLT2 inhibitors have over other antidiabetic classes?
SGLT2 inhibitors like empagliflozin have demonstrated cardiovascular and renal protective effects, leading to broader approval indications and increasing clinician adoption—enhancing market share beyond glucose control alone.

3. Are biosimilars influencing the market for linagliptin?
Yes. Post-patent expiry, biosimilars and generic versions are expected to lower prices and intensify competition, pressuring revenues for originator brands and prompting strategic responses like label expansion and cost reduction strategies.

4. How does metformin maintain its market dominance?
Metformin’s low cost, extensive clinical data, and inclusion as a first-line therapy underpin its widespread use, especially in resource-limited settings, despite limited innovation and modest growth.

5. What future innovations could affect this market segment?
Development of dual GIP/GLP-1 receptor agonists, continued validation of SGLT2 inhibitors’ cardiovascular benefits, and personalized medicine approaches could reshape treatment paradigms, influencing investment strategies.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 2021.
[2] Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(11):2117-2128.